Fujian Cosunter Pharmaceutical Co.,Ltd.(300436),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

300436 Fujian Cosunter Pharmaceutical Co.,Ltd.

Noon Closed 04-21 11:30:00

30.73

+1.05

+3.54%

High31.19	Low29.30	Vol2.33M
Open29.68	D1 Closing29.68	Amplitude6.37%
Mkt Cap4.89B	Tradable Cap4.21B	Total Shares159.00M
T/O71.01M	T/O Rate1.70%	Tradable Shares137.00M
P/B13.12	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"300436","market":"SZ","secType":"STK","nameCN":"Fujian Cosunter Pharmaceutical Co.,Ltd.","latestPrice":30.73,"timestamp":1745206566000,"preClose":29.68,"halted":0,"volume":2333600,"delay":0,"changeRate":0.0354,"floatShares":137000000,"shares":159000000,"eps":0.226,"marketStatus":"Noon Closed","change":1.05,"latestTime":"04-21 11:30:00","open":29.68,"high":31.19,"low":29.3,"amount":71010600,"amplitude":0.0637,"askPrice":30.73,"askSize":2,"bidPrice":30.72,"bidSize":24,"shortable":0,"etf":0,"ttmEps":0.226,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745211600000},"marketStatusCode":3,"adr":0,"adjPreClose":29.68,"symbolType":"stock","openAndCloseTimeList":[[1745199000000,1745206200000],[1745211600000,1745218800000]],"highLimit":32.65,"lowLimit":26.71,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":159267000,"isCdr":false,"pbRate":13.12,"roa":"--","peRate":135.973451,"roe":"--","epsLYR":-0.9814,"committee":0.536189,"marketValue":4894000000,"turnoverRate":0.0171,"status":0,"floatMarketCap":4201000000},"requestUrl":"/m/hq/s/300436","defaultTab":"news","newsList":[{"id":"2524406477","title":"Cosunter Pharmaceutical to Raise 977 Million Yuan From Planned Share Issuance; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2524406477","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524406477?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 13:36","pubTimestamp":1743658587,"startTime":"0","endTime":"0","summary":"Fujian Cosunter Pharmaceutical  plans to raise 976.9 million yuan from a planned share issuance, according to a Shenzhen Stock Exchange filing on Tuesday.The pharmaceutical company plans to issue 47.8 million shares.The plan is still subject to the approval of the Chinese securities regulator, the filing said.The company's shares fell over 4% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["300436","BK0239"],"gpt_icon":0},{"id":"2520695444","title":"Chinese Drug Regulator Accepts Clinical Trial Application of Cosunter Pharmaceutical's Unit for Two Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2520695444","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520695444?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 14:49","pubTimestamp":1742280587,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration accepted the application of Fujian Cosunter Pharmaceutical's  unit, Fujian Guangsheng ZhongLin Biotechnology, for the clinical trials of two drugs.The pharmaceutical company plans to trial GST-HG141 narecovir tablets and GST-HG131 tablets as treatment of hepatitis B patients, according to a Shenzhen Stock Exchange disclosure on Monday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["300436","BK0239"],"gpt_icon":0},{"id":"2509219639","title":"Cosunter Pharma's Unit Gets Nod to Trial Coronavirus Drug in Thailand","url":"https://stock-news.laohu8.com/highlight/detail?id=2509219639","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509219639?lang=en_us&edition=full_marsco","pubTime":"2025-02-06 14:16","pubTimestamp":1738822565,"startTime":"0","endTime":"0","summary":"Fujian Cosunter Pharmaceutical's  unit, Fujian Guangsheng Zhonglin Biotechnology, received approval from Thailand's drug administration to conduct clinical trials on a drug for the new coronavirus, according to a Shenzhen Stock Exchange disclosure on Wednesday.The atetegravir tablets or ritonavir tablets, traded as Tazovid, will be tested in Thailand, the pharmaceutical company said.The company's shares rose 1% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","300436"],"gpt_icon":0},{"id":"2491637105","title":"China Grants Fujian Cosunter Pharma Breakthrough Designation for Hepatitis B Drug; Shares Slide 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491637105","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491637105?lang=en_us&edition=full_marsco","pubTime":"2024-12-16 14:53","pubTimestamp":1734332028,"startTime":"0","endTime":"0","summary":"China's medical products administrator granted Fujian Cosunter Pharmaceutical  breakthrough therapy designation for its hepatitis B drug, according to a Monday filing with the Shenzhen Stock Exchange.The drug, with the generic name Neracorvir, will still have to undergo registration clinical research, the filing said.Shares fell 5% during Monday's afternoon trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","300436"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2015-04-22","address":"福建省宁德市柘荣县富源工业园区1-7幢","stockEarnings":[{"period":"1week","weight":0.027},{"period":"1month","weight":-0.1801},{"period":"3month","weight":-0.1556},{"period":"6month","weight":0.0392},{"period":"1year","weight":0.8965},{"period":"ytd","weight":-0.0915}],"companyName":"福建广生堂药业股份有限公司","boardCode":"AI0027","perCapita":"9763股","boardName":"医药制造业","registeredCapital":"15926万元","compareEarnings":[{"period":"1week","weight":0.0119},{"period":"1month","weight":-0.0437},{"period":"3month","weight":0.0108},{"period":"6month","weight":0.0047},{"period":"1year","weight":0.0659},{"period":"ytd","weight":-0.0224}],"survey":"　　福建广生堂药业股份有限公司的主营业务是核苷类抗乙肝病毒药物的研发、生产与销售。公司的主要产品是丙酚替诺福韦、替诺福韦、恩替卡韦、拉米夫定、阿德福韦酯五大核苷（酸）类抗乙肝病毒。公司获第二十三届中国国际高新技术成果交易会“优秀产品奖”。","serverTime":1745206595647,"listedPrice":21.47,"stockholders":"14003人(较上一季度减少15.49%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fujian Cosunter Pharmaceutical Co.,Ltd.(300436),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Fujian Cosunter Pharmaceutical Co.,Ltd.(300436) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Fujian Cosunter Pharmaceutical Co.,Ltd.,300436,Fujian Cosunter Pharmaceutical Co.,Ltd.股票,Fujian Cosunter Pharmaceutical Co.,Ltd.股票老虎,Fujian Cosunter Pharmaceutical Co.,Ltd.股票老虎国际,Fujian Cosunter Pharmaceutical Co.,Ltd.行情,Fujian Cosunter Pharmaceutical Co.,Ltd.股票行情,Fujian Cosunter Pharmaceutical Co.,Ltd.股价,Fujian Cosunter Pharmaceutical Co.,Ltd.股市,Fujian Cosunter Pharmaceutical Co.,Ltd.股票价格,Fujian Cosunter Pharmaceutical Co.,Ltd.股票交易,Fujian Cosunter Pharmaceutical Co.,Ltd.股票购买,Fujian Cosunter Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fujian Cosunter Pharmaceutical Co.,Ltd.(300436),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Fujian Cosunter Pharmaceutical Co.,Ltd.(300436) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction